New combo treatment shows promise for kids with rare bone marrow failure
NCT ID NCT07415083
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study reviewed medical records of 13 Korean children with severe aplastic anemia, a condition where the bone marrow stops making enough blood cells. Researchers wanted to see if adding eltrombopag to standard immunosuppressive therapy was safe and effective. Over 6 months, they tracked side effects and blood cell recovery. The goal was to improve blood counts without causing serious harm.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for APLASTIC ANEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Novartis
East Hanover, New Jersey, 07963, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a drug revive blood cell production in children with aplastic anemia?
- Could a platelet-boosting drug shorten recovery after stem cell transplants?
- A common antioxidant may help platelets recover faster after stem cell transplant
- Could a cancer antibody reboot blood production in aplastic anemia?
- Triple therapy aims to overcome antibody barrier in Half-Matched stem cell transplants
- Promising combo for aplastic anemia trial pulled before start